Cargando…

Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?

INTRODUCTION AND OBJECTIVE: In this study, we evaluated the influence of the transcript type on hematological and clinical parameters, as well as the event-free survival of 50 patients in the Chronic myeloid leukemia chronic phase. METHODS: We reviewed the medical records of 55 patients with Chronic...

Descripción completa

Detalles Bibliográficos
Autores principales: de Almeida Filho, T.P., Maia Filho, P.A., Barbosa, Maritza Cavalcante, Dutra, Luana Letícia Alves, Castro, Marilena Facundo de, Duarte, Fernando Barroso, Quixadá, Acy Telles de Souza, Lemes, Romélia Pinheiro Gonçalves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517615/
https://www.ncbi.nlm.nih.gov/pubmed/31079657
http://dx.doi.org/10.1016/j.htct.2018.10.003
_version_ 1783418313976578048
author de Almeida Filho, T.P.
Maia Filho, P.A.
Barbosa, Maritza Cavalcante
Dutra, Luana Letícia Alves
Castro, Marilena Facundo de
Duarte, Fernando Barroso
Quixadá, Acy Telles de Souza
Lemes, Romélia Pinheiro Gonçalves
author_facet de Almeida Filho, T.P.
Maia Filho, P.A.
Barbosa, Maritza Cavalcante
Dutra, Luana Letícia Alves
Castro, Marilena Facundo de
Duarte, Fernando Barroso
Quixadá, Acy Telles de Souza
Lemes, Romélia Pinheiro Gonçalves
author_sort de Almeida Filho, T.P.
collection PubMed
description INTRODUCTION AND OBJECTIVE: In this study, we evaluated the influence of the transcript type on hematological and clinical parameters, as well as the event-free survival of 50 patients in the Chronic myeloid leukemia chronic phase. METHODS: We reviewed the medical records of 55 patients with Chronic myeloid leukemia. The eligibility criteria were based on the availability of hematological and clinical baseline data in the medical records. Data on BCR-ABL transcripts were obtained from medical records. RESULTS: Eighteen patients (36%) had the b2a2 transcript, 24 (48%) had b3a2 and 8 (16%) had b2a2/b3a2. The median platelet count for transcripts b2a2, b3a2 and b2a2/b3a2 was 320.65 × 10(3)/L, 396 × 10(3)/L, and 327.05 × 10(3)/L, respectively (p = 0.896). We could not find any differences in relation to the other hematological parameters, when compared to the transcript type. Comparison between spleen and liver size and type of transcript did not differ inside the groups (p = 0.395 and p = 0.647, respectively) and the association between risk scores and transcript type did not show statistical significance (p > 0.05). The 21-month probability for event-free survival was 21%, 48% and 66% for the transcripts b2a2, b3a2 and b2a2/b3a2 respectively (p = 0.226) CONCLUSION: We conclude that the expression BCR-ABL transcripts have no influence on hematological, clinical and event-free survival parameters of patients in the Chronic myeloid leukemia chronic phase.
format Online
Article
Text
id pubmed-6517615
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Sociedade Brasileira de Hematologia e Hemoterapia
record_format MEDLINE/PubMed
spelling pubmed-65176152019-05-23 Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase? de Almeida Filho, T.P. Maia Filho, P.A. Barbosa, Maritza Cavalcante Dutra, Luana Letícia Alves Castro, Marilena Facundo de Duarte, Fernando Barroso Quixadá, Acy Telles de Souza Lemes, Romélia Pinheiro Gonçalves Hematol Transfus Cell Ther Original Article INTRODUCTION AND OBJECTIVE: In this study, we evaluated the influence of the transcript type on hematological and clinical parameters, as well as the event-free survival of 50 patients in the Chronic myeloid leukemia chronic phase. METHODS: We reviewed the medical records of 55 patients with Chronic myeloid leukemia. The eligibility criteria were based on the availability of hematological and clinical baseline data in the medical records. Data on BCR-ABL transcripts were obtained from medical records. RESULTS: Eighteen patients (36%) had the b2a2 transcript, 24 (48%) had b3a2 and 8 (16%) had b2a2/b3a2. The median platelet count for transcripts b2a2, b3a2 and b2a2/b3a2 was 320.65 × 10(3)/L, 396 × 10(3)/L, and 327.05 × 10(3)/L, respectively (p = 0.896). We could not find any differences in relation to the other hematological parameters, when compared to the transcript type. Comparison between spleen and liver size and type of transcript did not differ inside the groups (p = 0.395 and p = 0.647, respectively) and the association between risk scores and transcript type did not show statistical significance (p > 0.05). The 21-month probability for event-free survival was 21%, 48% and 66% for the transcripts b2a2, b3a2 and b2a2/b3a2 respectively (p = 0.226) CONCLUSION: We conclude that the expression BCR-ABL transcripts have no influence on hematological, clinical and event-free survival parameters of patients in the Chronic myeloid leukemia chronic phase. Sociedade Brasileira de Hematologia e Hemoterapia 2019 2019-02-16 /pmc/articles/PMC6517615/ /pubmed/31079657 http://dx.doi.org/10.1016/j.htct.2018.10.003 Text en © 2019 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
de Almeida Filho, T.P.
Maia Filho, P.A.
Barbosa, Maritza Cavalcante
Dutra, Luana Letícia Alves
Castro, Marilena Facundo de
Duarte, Fernando Barroso
Quixadá, Acy Telles de Souza
Lemes, Romélia Pinheiro Gonçalves
Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
title Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
title_full Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
title_fullStr Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
title_full_unstemmed Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
title_short Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
title_sort does bcr-abl transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517615/
https://www.ncbi.nlm.nih.gov/pubmed/31079657
http://dx.doi.org/10.1016/j.htct.2018.10.003
work_keys_str_mv AT dealmeidafilhotp doesbcrabltranscripttypeinfluencetheprognosisofpatientsinchronicmyelogenousleukemiachronicphase
AT maiafilhopa doesbcrabltranscripttypeinfluencetheprognosisofpatientsinchronicmyelogenousleukemiachronicphase
AT barbosamaritzacavalcante doesbcrabltranscripttypeinfluencetheprognosisofpatientsinchronicmyelogenousleukemiachronicphase
AT dutraluanaleticiaalves doesbcrabltranscripttypeinfluencetheprognosisofpatientsinchronicmyelogenousleukemiachronicphase
AT castromarilenafacundode doesbcrabltranscripttypeinfluencetheprognosisofpatientsinchronicmyelogenousleukemiachronicphase
AT duartefernandobarroso doesbcrabltranscripttypeinfluencetheprognosisofpatientsinchronicmyelogenousleukemiachronicphase
AT quixadaacytellesdesouza doesbcrabltranscripttypeinfluencetheprognosisofpatientsinchronicmyelogenousleukemiachronicphase
AT lemesromeliapinheirogoncalves doesbcrabltranscripttypeinfluencetheprognosisofpatientsinchronicmyelogenousleukemiachronicphase